A current weblog publish mentioned a newly accredited imaging agent with an unwieldy identify: gallium-68 PMA-11. Delivered in small quantities by injection, this minimally radioactive tracer sticks to prostate most cancers cells, which subsequently glow and reveal themselves on a positron emission tomography (PET) scan. Provided to males with rising PSA ranges after preliminary prostate most cancers therapy (a situation referred to as biochemical recurrence), this type of imaging can permit docs to search out and deal with new tumors that they may in any other case miss. With at present obtainable imaging expertise, such tumors may probably escape detection till they have been bigger and extra harmful.
However whereas gallium-68 PMA-11 is the most recent PET tracer to win FDA approval, not everybody can get it. In america, it’s at present obtainable solely to sufferers handled on the College of California, Los Angeles, or the College of California, San Francisco, the place the tracer is manufactured. Nonetheless, two different PET tracers accredited for prostate most cancers imaging within the US have gotten extra accessible.
In January 2021, a group at Stanford College revealed findings exhibiting that one these tracers, referred to as fluciclovine F18 (commerce identify Axumin), recognized considerably extra metastatic cancers than different standard kinds of imaging. Axumin was accredited in 2016, and these are among the many first information to point out how nicely the tracer performs in real-world settings.
The Stanford researchers reviewed medical information from 165 males who had been given Axumin PET scans between September 2017 and December 2019. All the boys had biochemical recurrence, and 70 of them have been additionally imaged with different applied sciences, together with CT scans, bone scans, or MRIs.
Axumin PET scans outperformed all the opposite checks with respect to tumor detection. In all, 110 males had PET-detected metastases, and nobody with a adverse PET scan was optimistic for most cancers on different imaging checks. PET imaging discovered most cancers in 9 of 31 males who had adverse outcomes on CT scans. Equally, six of 31 males with adverse outcomes on an MRI had PET-detected tumors. The expertise additionally detected skeletal tumors in a single man with a adverse bone scan.
Importantly, tumor detection charges have been biggest for males with excessive and quickly rising PSA ranges. That’s to be anticipated, since prostate most cancers cells launch PSA; as tumors develop and proliferate, PSA ranges will rise in tandem. Actually, prior analysis exhibits that Axumin PET scans are unlikely to detect most cancers if PSA is lower than 1 nanogram per deciliter (ng/mL) in blood.
Optimistic PET scans additionally led to therapies that docs may not have began if solely adverse findings with different imaging checks have been obtainable. A lot of the 102 males who have been subsequently handled obtained radiation delivered particularly to the tumor websites, in some cases mixed with medicine that block testosterone, a hormone that speeds prostate most cancers development.
The examine had some limitations, together with that it was performed at just one facility. Moreover, in solely seven circumstances have been PET findings confirmed by a pathologist’s overview of eliminated tissue samples. That’s as a result of typically, the detected lesions have been too small — lower than a centimeter in measurement — to biopsy. PET-detected cancers have been confirmed as a substitute by declines in PSA after therapy.
“Axumin scanning, together with newly developed gallium scanning, is altering the way in which during which prostate most cancers is staged and in the end handled,” says Dr. Marc Garnick, the Gorman Brothers Professor of Drugs at Harvard Medical Faculty and Beth Israel Deaconess Medical Middle, editor of the Harvard Well being Publishing Annual Report on Prostate Illnesses, and editor in chief of HarvardProstateKnowledge.org. “The elevated sensitivity of those new scanning applied sciences is each figuring out sufferers with metastatic illness who in any other case would have been thought of to be freed from metastases, in addition to serving to to substantiate the absence of metastatic deposits. Each conditions will alter that method during which therapy selections are made, and it will present extra precision by way of what we are able to provide our sufferers. These new applied sciences are excellent news for docs and sufferers alike.”
Commenting has been closed for this publish.